DAVIS, Calif., Aug. 29, 2017 -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for agriculture, turf and ornamental and water treatment markets, today announced that management will attend the Rodman & Renshaw 19th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 11-12, 2017.
Marrone Bio Innovations management will host one-on-one meetings throughout both days and is scheduled to present as follows:
Rodman & Renshaw 19th Annual Global Investment Conference
Date: Monday, September 11, 2017
Presentation Time: 10:25 a.m. ET
Location: Lotte New York Palace Hotel – 455 Madison Ave, New York, NY 10022
Webcast: http://wsw.com/webcast/rrshq27/mbii
Registration is mandatory. For more information about the conference or to schedule a one-on-one meeting, please contact your Rodman & Renshaw representative.
About Marrone Bio Innovations
Smart. Natural. Solutions.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI currently has six commercially available products (Regalia®, Grandevo®, Venerate®, Majestene®, Haven™ and Zequanox®) as well as eight product candidates in various stages of the company’s rapid development pipeline. MBI also distributes Bio-tam 2.0® for Isagro USA in the western U.S. and Jet-Ag® for Jet Harvest in most regions of the U.S.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding sales of the Company’s products, the potential benefits of the Company’s products, and MBI’s efforts with respect to expansion of its product labels in international markets. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products vin global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.
Marrone Bio Innovations Contacts: Pam Marrone, CEO and Founder Telephone: +1 (530) 750-2800 Email: [email protected] Investor Relations: Greg Falesnik Managing Director MZ Group – MZ North America Main: 949-385-6449 [email protected] www.mzgroup.us


Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 



